How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,236 results for

Dexamethasone Suppression Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.

Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2018 Clinical Trials

2. Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test. (PubMed)

Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test. The overnight dexamethasone (DXM) suppression test (DST) has high sensitivity, but moderate specificity, for diagnosing hypercortisolism. We have evaluated if simultaneous measurement of S-DXM may correct for variable DXM bioavailability and increase the diagnostic performance of DST, and if saliva (sa) is a feasible adjunct or alternative to serum.Prospective study of DST (...) and cortisol reduced false-positive DSTs by 20% and improved the specificity. S-DXM >3.3 nmol/L is sufficient for the suppression of cortisol <50 nmol/L. Measurement of glucocorticoids in saliva is a non-invasive and easy procedure and post-DST sa-cortisone was found particularly useful in the diagnosis of CS.© 2017 European Society of Endocrinology.

Full Text available with Trip Pro

2017 European Journal of Endocrinology

3. Evaluation of individual low‐dose dexamethasone suppression test patterns in naturally occurring hyperadrenocorticism in dogs (PubMed)

Evaluation of individual low‐dose dexamethasone suppression test patterns in naturally occurring hyperadrenocorticism in dogs Dogs with hyperadrenocorticism (HAC) may be more mildly affected at the time of diagnosis today, which could influence the prevalence of associated clinical and clinicopathological abnormalities and diagnostic test performance. Different low-dose dexamethasone suppression test (LDDST) result patterns have not been evaluated individually.To assess the current features (...) of HAC and evaluate if the diagnostic test performance of individual LDDST result patterns differ.One hundred and twenty-three dogs undergoing investigation for HAC.Retrospective evaluation of dogs in which a LDDST was performed and HAC confirmed or excluded by alternative means. Cases with basal cortisol concentrations (t0 ) < 1 μg/dL were excluded. Each LDDST result was classified as (a) complete suppression (t3 and t8  < 1 μg/dL), (b) lack of suppression (t3 and t8  > 1 μg/dL and both > 50% t0

Full Text available with Trip Pro

2018 Journal of Veterinary Internal Medicine

5. The Very Low-Dose Dexamethasone Suppression Test in the General Population: A Cross-Sectional Study. (PubMed)

The Very Low-Dose Dexamethasone Suppression Test in the General Population: A Cross-Sectional Study. Determinants of the hypothalamic-pituitary-adrenal (HPA) axis functioning are increasingly explored in population-based studies. However, functional tests measuring the negative feedback of the HPA axis cannot easily be implemented into large observational studies. Furthermore, high doses of dexamethasone often completely suppress the HPA axis in healthy persons. This study aimed to detect (...) the effects of the health, lifestyle and sociodemographic factors, psychiatric problems and cognitive functions on the negative feedback of the HPA axis using a very low-dose (0.25 mg) dexamethasone suppression test (DST).We evaluated the associations of several determinants with the saliva cortisol concentrations after dexamethasone intake in a confounder-adjusted model also corrected for baseline saliva cortisol concentrations in the Rotterdam Study, a large population-based study (N = 1822). We found

Full Text available with Trip Pro

2016 PLoS ONE

6. Efficacy of dexamethasone suppression test during the diagnosis of primary pigmented nodular adrenocortical disease in Chinese adrenocorticotropic hormone-independent Cushing syndrome (PubMed)

Efficacy of dexamethasone suppression test during the diagnosis of primary pigmented nodular adrenocortical disease in Chinese adrenocorticotropic hormone-independent Cushing syndrome To evaluate the cut-off value of the ratio of 24 h urinary free cortisol (24 h UFC) levels post-dexamethasone to prior-dexamethasone in dexamethasone suppression test (DST) during the diagnosis of primary pigmented nodular adrenocortical disease in Chinese adrenocorticotropic hormone-independent Cushing (...) syndrome.Retrospective study.The patients diagnosed with primary pigmented nodular adrenocortical disease (PPNAD, n = 25), bilateral macronodular adrenal hyperplasia (BMAH, n = 27), and adrenocortical adenoma (ADA, n = 84) were admitted to the Peking Union Medical College Hospital from 2001 to 2016.Serum cortisol, adrenocorticotropic hormone (ACTH), and 24 h UFC were measured before and after low-dose dexamethasone suppression test (LDDST) and high-dose dexamethasone suppression test (HDDST).After LDDST and HDDST

Full Text available with Trip Pro

2017 Endocrine

7. Clinical Utility of the Adrenocorticotropin Stimulation Test with/without Dexamethasone Suppression for Definitive and Subtype Diagnosis of Primary Aldosteronism (PubMed)

Clinical Utility of the Adrenocorticotropin Stimulation Test with/without Dexamethasone Suppression for Definitive and Subtype Diagnosis of Primary Aldosteronism The adrenocorticotropin (ACTH) stimulation test (AST) has been reported to be useful for diagnosing primary aldosteronism (PA), particularly for differentiating PA subtypes under 1-mg dexamethasone suppression (DS). The aim of our study was to clarify the effect of 1-mg DS on AST results. A retrospective cohort study was conducted (...) using data for 48 patients (PA: 30/48). We estimated the difference in plasma aldosterone concentration (PAC) responsiveness to ACTH stimulation with single (AST alone) and combined (AST under 1-mg DS) tests within the same patient. We compared the diagnostic accuracy of these two tests for PA and the laterality of hyperaldosteronism. We found no differences in PAC responsiveness to ACTH stimulation between single and combined tests, and observed a significant positive linear relationship (30 min, R

Full Text available with Trip Pro

2017 International journal of molecular sciences

8. Performance of the 1 mg dexamethasone suppression test in patients with severe obesity. (PubMed)

Performance of the 1 mg dexamethasone suppression test in patients with severe obesity. To analyze the performance of the 1 mg dexamethasone suppression test (DST) in patients with obesity. Special attention was paid to the influence of interfering medication on DST.In this prospective cohort study (Mannheim Obesity Study), patients with obesity were evaluated before bariatric surgery. For evaluation of hypercortisolism, a 1 mg dexamethasone-suppression test (DST) in all subjects was performed (...) . Medication was assessed for possible interference.Two hundred seventy-eight patients with a mean age of 42.3 years (68.8% women) and a mean BMI of 47.9 ± 8.4 kg/m(2) were screened. Insufficient suppression of cortisol after DST was found in 24 patients (8.6%). In two patients hypercortisolism was confirmed. The specificity for DST was calculated at 92.0%. Only CYP3A4 inducers (n = 22, 7.9%) and estrogen therapy (n = 17, 6.1%) were significantly associated with falsely elevated cortisol after DST

Full Text available with Trip Pro

2016 Obesity

9. The influence of oral contraceptives on overnight 1 mg dexamethasone suppression test. (PubMed)

The influence of oral contraceptives on overnight 1 mg dexamethasone suppression test. In suspected hypercortisolism, the 1 mg dexamethasone suppression test is the usual initial test. In fertile women, false-positive test results are often due to the use of oral contraceptives. By elevating cortisol-binding globulin these contraceptives increase the total serum cortisol concentration. The aim of this study was to assess the duration and degree of influence of oral contraceptives on the low (...) -dose dexamethasone suppression test.Thirteen healthy female volunteers without symptoms or signs of overt hypercortisolism, aged 18-55 years, who were using oral contraceptives, underwent a 1 mg dexamethasone suppression test. Tests were repeated one and six weeks after withdrawal of the contraceptive. In addition, 24-hour urinary cortisol excretion and late-night salivary cortisol were measured.Of the 13 volunteers (62%) eight had inadequate suppression of cortisol by 1 mg dexamethasone while

2016 Netherlands Journal of Medicine

10. Nonsuppressible Oral Dexamethasone Suppression Tests but Not Cushing Syndrome (PubMed)

Nonsuppressible Oral Dexamethasone Suppression Tests but Not Cushing Syndrome In spite of the presence of definitive diagnostic criteria to diagnose Cushing syndrome diagnosis may become challenging. We report a young female with mild clinical features of Cushing syndrome, who had nonsuppressible oral dexamethasone suppression tests; also she had a suspicious pituitary lesion. She underwent pituitary surgery and a pituitary microadenoma (non-ACTH staining) was removed. Now she had come to us (...) with similar complaints to those before. Again she had nonsuppressible oral dexamethasone suppression tests. As the diurnal variation of serum and salivary cortisol was maintained and urinary free cortisol was normal, further evaluation with IV dexamethasone suppression test was performed which clearly ruled out Cushing syndrome. The patient was not on any medicines known to alter dexamethasone metabolism. Fat malabsorption was also ruled out using appropriate tests. The reason for this discrepancy

Full Text available with Trip Pro

2016 Case reports in endocrinology

11. Dexamethasone Suppression Test

Dexamethasone Suppression Test Dexamethasone Suppression Test Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Dexamethasone (...) Suppression Test Dexamethasone Suppression Test Aka: Dexamethasone Suppression Test , Low-Dose Dexamethasone Suppression Test II. Background Two stage testing described below will miss cases The low dose (1 mg) test is not adequately sensitive III. Indications: Cushing's Disease Screening Second line test Start with IV. Mechanism Test measures response to ACTH ACTH should decrease in response to Decreased ACTH should result in decreased Cortisol Failure for cortisol to suppress suggests 2 causes ACTH over

2018 FP Notebook

12. Aldosterone Suppression by Dexamethasone in Patients with KCNJ5-Mutated Aldosterone-producing Adenoma. (PubMed)

(KCNJ5) mutations remains unknown.To investigate KCNJ5 genotype-specific differences in aldosterone biosynthesis in response to ACTH stimulation.A cross-sectional study through retrieval of clinical records.One hundred forty-one patients aged ≥20 years with APA were examined.Associations between KCNJ5 mutations and clinical parameters reflecting the renin-angiotensin system [saline infusion test (SIT)] and ACTH pathways [dexamethasone suppression test (DST)].KCNJ5 mutations were detected in 107 cases (...) Aldosterone Suppression by Dexamethasone in Patients with KCNJ5-Mutated Aldosterone-producing Adenoma. Aldosterone biosynthesis is regulated principally by ACTH and gene mutations as well as by angiotensin II and serum potassium. In addition, previous studies have reported the potential effects of KCNJ5 mutations in aldosterone-producing adenoma (APA) on cardiovascular diseases. However, responsiveness to ACTH in APAs according to potassium inwardly rectifying channel, subfamily J, member 5

2018 Journal of Clinical Endocrinology and Metabolism

13. miR-365 Ameliorates Dexamethasone-Induced Suppression of Osteogenesis in MC3T3-E1 Cells by Targeting HDAC4 (PubMed)

miR-365 Ameliorates Dexamethasone-Induced Suppression of Osteogenesis in MC3T3-E1 Cells by Targeting HDAC4 Glucocorticoid administration is the leading cause of secondary osteoporosis. In this study, we tested the hypotheses that histone deacetylase 4 (HDAC4) is associated with glucocorticoid-induced bone loss and that HDAC4 dependent bone loss can be ameliorated by miRNA-365. Our previous studies showed that miR-365 mediates mechanical stimulation of chondrocyte proliferation (...) and differentiation by targeting HDAC4. However, it is not clear whether miR-365 has an effect on glucocorticoid-induced osteoporosis. We have shown that, in MC3T3-E1 osteoblasts, dexamethasone (DEX) treatment decreased the expression of miR-365, which is accompanied by the decrease of cell viability in a dose-dependent manner. Transfection of miR-365 ameliorated DEX-induced inhibition of MC3T3-E1 cell viability and alkaline phosphatase activity, and attenuated the suppressive effect of DEX on runt-related

Full Text available with Trip Pro

2017 International journal of molecular sciences

14. ABNORMAL RESPONSIVENESS TO DEXAMETHASONE-SUPPRESSED CRH TEST IN PATIENTS WITH BILATERAL ADRENAL INCIDENTALOMAS. (PubMed)

ABNORMAL RESPONSIVENESS TO DEXAMETHASONE-SUPPRESSED CRH TEST IN PATIENTS WITH BILATERAL ADRENAL INCIDENTALOMAS. The bilateral formation of nodules indicates that the pathogenesis of bilateral adrenal incidentalomas (AI) may differ from that of unilateral AI. A possible role of hypothalamo-pituitary-adrenal (HPA) axis dysregulation in their formation has not been investigated.The objective of the study was to evaluate the presence of altered feedback regulation of HPA axis in patients (...) with bilateral AI.The dexamethasone (DEX) suppression-CRH test was used to assess ACTH and cortisol responses in controls and patients with unilateral and bilateral AI.The study was conducted at endocrine departments of two tertiary centers.We studied 24 controls and 39 patients with unilateral and 46 with bilateral AI.All subjects underwent standard low-dose dexamethasone suppression followed by iv bolus administration of human CRH (100 μg).Bilateral AI had higher levels of ACTH and cortisol after the DEX

Full Text available with Trip Pro

2015 Journal of Clinical Endocrinology and Metabolism

15. Dexamethasone-suppressed Salivary Cortisol and Pain Sensitivity in Female Twins. (PubMed)

Dexamethasone-suppressed Salivary Cortisol and Pain Sensitivity in Female Twins. Hypothalamic-pituitary-adrenal (HPA) axis dysregulation is associated with chronic pain. Studying pain sensitivity and the HPA axis could elucidate the role of stress in chronic pain development, which might be influenced by familial factors, including genes.Associations between pain sensitivity and salivary cortisol and familial confounding in these associations were examined in 88 female, community-based twin (...) pairs (75% monozygotic, mean age 29 y). Cortisol was assessed after 0.25 mg dexamethasone (DEX), recovery from 0.25 mg DEX, and after 0.5 mg DEX. Cold pressor task (CPT) pain ratings were obtained at threshold and at tolerance. Conditioned pain modulation (CPM) was examined using thermal heat as the testing stimulus and hot water as the conditioning stimulus. Generalized estimating equation models were used and adjusted for baseline pain rating, age, and other relevant covariates.After controlling

Full Text available with Trip Pro

2016 Clinical Journal of Pain

16. Dexamethasone Suppression FDG PET/CT for Differentiating between True- and False-Positive Pulmonary and Mediastinal Lymph Node Metastases in Non-Small Cell Lung Cancer: A Pilot Study of FDG PET/CT after Oral Administration of Dexamethasone. (PubMed)

signed-rank, Kruskal-Wallis, or Spearman rank correlation tests were used as necessary for statistical evaluations.In 17 primary lesions, no significant difference was noted in visual score between baseline (mean, 3.4 ± 1.2) and dexamethasone suppression scans (mean, 3.3 ± 1.2; P = .16), although SUVmax was significantly lower on dexamethasone suppression scans (mean, 7.1 ± 5.2) than on baseline scans (mean, 8.6 ± 6.6; P = .005). In eight nodes with true-positive (TP) findings, there were (...) Dexamethasone Suppression FDG PET/CT for Differentiating between True- and False-Positive Pulmonary and Mediastinal Lymph Node Metastases in Non-Small Cell Lung Cancer: A Pilot Study of FDG PET/CT after Oral Administration of Dexamethasone. To examine whether dexamethasone suppression can reduce fluorine 18 fluorodeoxyglucose (FDG) uptake in false-positive (FP) findings in pulmonary and mediastinal lymph nodes in non-small cell lung cancer (NSCLC).Institutional ethics review board approved

2015 Radiology

17. Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers. (PubMed)

Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers. The hypothalamic-pituitary-adrenal (HPA) axis is dysfunctional in a subgroup of mood disorders.We compared cortisol and adrenocorticotropic hormone (ACTH) responses in major depression and healthy volunteers to the combined dexamethasone suppression-corticotrophin-releasing hormone stimulation (DEX-CRH) test. Unlike other published studies, the study (...) patients were medication-free and the healthy volunteers did not have first-degree relatives with a mood or psychotic disorder. Demographics, DSM-IV diagnoses and other clinical parameters were evaluated in major depressive disorder (MDD) and healthy control groups. Participants received an oral dose of 1.5mg dexamethasone at 11 pm the day before CRH administration. On the following day, at 3 pm, 100 µg of ovine CRH was infused. Blood samples for determination of cortisol and ACTH were collected every

2013 Journal of Affective Disorders

18. Charge based intra-cartilage delivery of single dose dexamethasone using Avidin nano-carriers suppresses cytokine-induced catabolism long term. (PubMed)

Charge based intra-cartilage delivery of single dose dexamethasone using Avidin nano-carriers suppresses cytokine-induced catabolism long term. Avidin exhibits ideal characteristics for targeted intra-cartilage drug delivery: its small size and optimal positive charge enable rapid penetration through full-thickness cartilage and electrostatic binding interactions that give long half-lives in vivo. Here we conjugated Avidin with dexamethasone (DEX) and tested the hypothesis that single-dose (...) and biosynthesis rates were measured using DMMB assay and (35)S-incorporation, respectively. Chondrocyte viability was measured using fluorescence staining.Ester linker released DEX from Avidin significantly faster than hydrazone under physiological buffer conditions. Single dose Avidin-DEX suppressed cytokine-induced sGAG loss over 3-weeks, rescued IL-1α-induced cell death, and restored sGAG synthesis levels without causing cytotoxicity. The two Avidin-DEX conjugates in 1:1 combination (fast:slow) had

Full Text available with Trip Pro

2015 Osteoarthritis and Cartilage

19. Dexamethasone-suppressed cortisol awakening response predicts treatment outcome in posttraumatic stress disorder. (PubMed)

Dexamethasone-suppressed cortisol awakening response predicts treatment outcome in posttraumatic stress disorder. Posttraumatic stress disorder (PTSD) has been associated with several alterations in the neuroendocrine system, including enhanced cortisol suppression in response to the dexamethasone suppression test. The aim of this study was to examine whether specific biomarkers of PTSD predict treatment success in trauma-focused psychotherapy.Data were collected in the context of a randomized (...) controlled trial comparing two forms of trauma-focused psychotherapy. Basal cortisol and dehydroepiandrosterone sulfate levels, and the response to the dexamethasone suppression test were assessed pre-treatment in 24 PTSD patients. Treatment success was measured by pre- to post-treatment decrease in self-reported PTSD severity.A more suppressed cortisol curve after dexamethasone significantly predicted greater PTSD symptom decrease in trauma-focused psychotherapy, independent of the effects of gender

2015 Journal of Affective Disorders

20. The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)

The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs) Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.4, +31 January 2019] Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment C-REACTIVE PROTEIN POINT-OF-CARE (...) TESTING (CRP POCT) TO GUIDE ANTIBIOTIC PRESCRIBING IN PRIMARY CARE SETTINGS FOR ACUTE RESPIRATORY TRACT INFECTIONS (RTIS) Project ID: OTCA012 C-reactive protein point-of-care testing to guide antibiotic prescribing for acute respiratory tract infections in primary care EUnetHTA Joint Action 3 WP4 2 DOCUMENT HISTORY AND CONTRIBUTORS Version Date Description V1.0 26/10/2018 First draft. V1.1 03/12/2018 Input from co-author has been processed. V1.2 03/12/2018 Input from dedicated reviewers has been

2019 EUnetHTA

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>